| This is the talk page for discussing improvements to the Ellipta article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Ellipta.
|
Trelegy Ellipta edit
According to:
"Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US" (Press release). GlaxoSmithKline. 18 September 2017.
Trelegy Ellipta = fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI).
A news item related to a study on this agent: "GlaxoSmithKline: IMPACT Study Shows Benefits Of Trelegy Ellipta In COPD Patients". AFX News. 19 April 2018. Retrieved 2018-04-20.
--User:Ceyockey (talk to me) 01:58, 21 April 2018 (UTC)
Anoro edit
How can you get it without insurance and a reasonable price 74.69.156.226 (talk) 14:29, 27 October 2023 (UTC)